FindTrial
Sign In

[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514759-13-01
Enrollment
15
Registered
2024-12-16
Start date
2024-12-16
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

The number of individuals with PET-positive lesions and the distribution of PET-positive lesions.

Detailed description

The correlation between PET outcome and development of PsA in 2 years follow-up, The quantitative [18F]Fluoride uptake in PET-positive lesions

Interventions

DRUGSodium Fluoride (18F) Life Radiopharma 0
DRUG1 - 4 GBq/ml solution injectable

Sponsors

Stichting Amsterdam UMC
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The number of individuals with PET-positive lesions and the distribution of PET-positive lesions.—

Secondary

MeasureTime frame
The correlation between PET outcome and development of PsA in 2 years follow-up, The quantitative [18F]Fluoride uptake in PET-positive lesions—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026